See more : B.A.G. Films and Media Limited (BAGFILMS.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Biohaven Pharmaceutical Holding Company Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Nippon Electric Glass Co., Ltd. (NPEGF) Income Statement Analysis – Financial Results
- American Eagle Gold Corp. (AE.V) Income Statement Analysis – Financial Results
- NuGenerex Immuno-Oncology, Inc. (NUGX) Income Statement Analysis – Financial Results
- Bio-Gene Technology Limited (BGT.AX) Income Statement Analysis – Financial Results
- Fortitude Group, Inc. (FRTD) Income Statement Analysis – Financial Results
Biohaven Pharmaceutical Holding Company Ltd. (BHVN)
About Biohaven Pharmaceutical Holding Company Ltd.
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2017 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 462.51M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 3.37M | 1.39M | 91.66M | 72.00K | 0.00 | 0.00 |
| Gross Profit | -3.37M | -1.39M | 370.85M | -72.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 80.18% | 0.00% | 0.00% | 0.00% |
| Research & Development | 373.28M | 437.07M | 181.49M | 98.46M | 344.67M | 0.00 |
| General & Administrative | 56.90M | 130.86M | 37.41M | 16.05M | 134.45M | 0.00 |
| Selling & Marketing | 5.87M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 62.77M | 130.86M | 37.41M | 16.05M | 134.45M | 0.00 |
| Other Expenses | 0.00 | -1.91M | 1.21M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 436.05M | 567.93M | 218.90M | 114.51M | 479.12M | 0.00 |
| Cost & Expenses | 436.05M | 567.93M | 218.90M | 114.51M | 479.12M | 0.00 |
| Interest Income | 17.73M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | -12.71M | 0.00 |
| Depreciation & Amortization | 6.91M | 1.39M | 1.39M | 72.00K | 171.86K | 52.52K |
| EBITDA | -429.14M | -462.80M | -217.51M | -114.43M | -479.12M | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | -47.03% | 0.00% | 0.00% | 0.00% |
| Operating Income | -436.05M | -567.93M | -218.90M | -114.51M | -479.12M | 0.00 |
| Operating Income Ratio | 0.00% | 0.00% | -47.33% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 26.50M | -1.91M | 6.47M | -4.16M | -49.26M | 0.00 |
| Income Before Tax | -409.55M | -569.84M | -212.43M | -118.67M | -528.39M | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | -45.93% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -1.38M | 438.00K | 1.37M | -134.30K | 419.00K | 0.00 |
| Net Income | -408.17M | -570.28M | -213.80M | -118.67M | -528.81M | 0.00 |
| Net Income Ratio | 0.00% | 0.00% | -46.23% | 0.00% | 0.00% | 0.00% |
| EPS | -5.73 | -12.75 | -5.97 | -3.31 | -10.91 | 0.00 |
| EPS Diluted | -5.73 | -12.75 | -5.97 | -3.31 | -10.91 | 0.00 |
| Weighted Avg Shares Out | 71.20M | 44.74M | 35.82M | 35.82M | 48.49M | 0.00 |
| Weighted Avg Shares Out (Dil) | 71.20M | 44.74M | 35.82M | 35.82M | 48.49M | 0.00 |
Are Medical Stocks Lagging Biohaven Ltd. (BHVN) This Year?
Here's Why Momentum in Biohaven Ltd. (BHVN) Should Keep going
Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek®
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
Biohaven Announces Pricing of $225 Million Public Offering of Common Shares
BIOHAVEN ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES
Biohaven (BHVN) Up on Positive Data from Autoimmune Disease Drug
Biohaven, Yet Another Argenx Rival In Autoimmune Drugs, Just Rocketed 29%
Why Biohaven Stock Is Skyrocketing Today
Biohaven Completes Enrollment in Pivotal Phase 3 Study of Taldefgrobep Alfa in Spinal Muscular Atrophy
Source: https://incomestatements.info
Category: Stock Reports